Strides Pharma names Nandini Matiyani Global Head of HR

Strides Pharma Science has appointed Nandini Matiyani as Executive Vice President and Global Head of Human Resources, strengthening the company’s leadership bench as it scales its global operations.

In a post on LinkedIn, Matiyani said she was “embarking on a new journey” with Strides and will lead the global HR function across the pharmaceutical group’s international footprint. She thanked Chairman Arun Kumar, Managing Director and Group CEO Badri Srinivasan, and the board for their confidence in her appointment.

Matiyani brings more than 20 years of experience in people strategy, cultural transformation and HR leadership across multinational and publicly listed organisations. She said her focus at Strides will be on strengthening capabilities, reinforcing culture and supporting the company’s ambition to deliver “better and fairer healthcare” through agility, innovation and meaningful people practices.

Strides, established in 1990 and headquartered in Bengaluru, operates in more than 100 countries, supplying regulated markets, donor-funded channels and its “in Africa for Africa” business. The company manufactures complex pharmaceutical products from sites in India, Italy, Kenya and the United States.

Matiyani said she looks forward to working with teams across geographies to build talent strength and organisational capacity as Strides accelerates its global agenda. Her appointment underscores the company’s focus on leadership development and culture building as it competes in highly regulated and cost-sensitive markets.

The company has not announced further organisational changes, but the expanded HR leadership role signals a sharper emphasis on people systems and capability building as Strides targets growth across key markets.

Related Posts

Licences of 20 medical stores suspended after inspections

Drug Control Department inspects 120 medical stores; 32 NDPS cases and 63 arrests recorded in 2026 so far The district administration has intensified action against illegal drug sale and distribution,…

Bain Capital sells nearly 1 pc stake in Emcure Pharma for Rs 289 crore

NEW DELHI: Global investment firm Bain Capital has divested nearly a 1 per cent stake in Emcure Pharmaceuticals for over Rs 289 crore through open market transactions, according to the…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Licences of 20 medical stores suspended after inspections

Licences of 20 medical stores suspended after inspections

Bain Capital sells nearly 1 pc stake in Emcure Pharma for Rs 289 crore

Bain Capital sells nearly 1 pc  stake in Emcure Pharma for Rs 289 crore

Sun Pharma to acquire U.S. firm Organon in $11.75 billion deal

Sun Pharma to acquire U.S. firm Organon in $11.75 billion deal

HP accounts for 47 inferior drugs in March alert

HP accounts for 47 inferior drugs in March alert

Civil society group SAM calls for greater transparency involving clinical trials

Civil society group SAM calls for greater transparency involving clinical trials

Different packaging, typos expose fake Mounjaro racket

Different packaging, typos expose fake Mounjaro racket